Regeneron Pharmaceuticals, Inc. $REGN Position Increased by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.6% in the 3rd quarter, Holdings Channel.com reports. The fund owned 26,693 shares of the biopharmaceutical company’s stock after acquiring an additional 2,113 shares during the quarter. Rakuten Investment Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $20,033,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of REGN. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $5,682,636,000. State Street Corp grew its stake in shares of Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after purchasing an additional 170,210 shares during the period. Bank of America Corp DE increased its holdings in Regeneron Pharmaceuticals by 2.8% in the first quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock valued at $919,120,000 after buying an additional 32,158 shares in the last quarter. Amundi increased its stake in shares of Regeneron Pharmaceuticals by 27.5% in the 1st quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company’s stock valued at $780,210,000 after purchasing an additional 217,892 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $473,872,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

Wall Street Analyst Weigh In

Several research firms have commented on REGN. Wells Fargo & Company boosted their price objective on Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the stock an “equal weight” rating in a research note on Monday. Citigroup upped their price target on Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the company a “neutral” rating in a research note on Friday, October 30th. HSBC lifted their price objective on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Truist Financial upped their target price on shares of Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the stock an “equal weight” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $898.97.

Regeneron Pharmaceuticals Trading Down 4.4%

Shares of REGN opened at $930.67 on Thursday. The company has a current ratio of 3.35, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The firm’s 50-day moving average is $800.69 and its two-hundred day moving average is $741.11. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $991.73. The firm has a market capitalization of $95.82 billion, a P/E ratio of 20.55, a PEG ratio of 1.45 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same quarter in the previous year, the business posted $11.83 earnings per share. The firm’s quarterly revenue was up 36.3% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 51.64 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.30%.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 800 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joseph J. Larosa sold 4,466 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the completion of the transaction, the executive vice president directly owned 38,906 shares in the company, valued at approximately $37,563,353.94. This represents a 10.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 20,789 shares of company stock valued at $18,766,698 over the last 90 days. 6.97% of the stock is currently owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.